Last reviewed · How we verify
Desloratadine placebo tablet
This is a placebo tablet containing no active pharmaceutical ingredient and therefore has no mechanistic effect.
This is a placebo tablet containing no active pharmaceutical ingredient and therefore has no mechanistic effect. Used for Clinical trial control (not a therapeutic indication).
At a glance
| Generic name | Desloratadine placebo tablet |
|---|---|
| Also known as | Aerius, Clarinex, SCH 34117, descarboethoxyloratadine, Aerus |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
A placebo is an inert formulation used as a control in clinical trials to assess the efficacy of an active drug by comparison. It produces no pharmacological action and serves only as a reference standard to distinguish true drug effects from placebo response.
Approved indications
- Clinical trial control (not a therapeutic indication)
Common side effects
Key clinical trials
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) (PHASE4)
- Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836) (PHASE4)
- A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) (PHASE4)
- A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) (PHASE4)
- A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) (PHASE4)
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054) (PHASE4)
- A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200) (PHASE3)
- An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desloratadine placebo tablet CI brief — competitive landscape report
- Desloratadine placebo tablet updates RSS · CI watch RSS
- Organon and Co portfolio CI